New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 24, 2014
04:55 EDTEW, EW, EW, EW, EW, QDEL, QDEL, QDEL, QDEL, QDEL, SQNM, SQNM, SQNM, SQNM, SQNM, TNDM, TNDM, TNDM, TNDM, TNDM, VOLC, VOLC, VOLC, VOLC, VOLC, ATEC, ATEC, ATEC, ATEC, ATEC, CFN, CFN, CFN, CFN, CFN, ICUI, ICUI, ICUI, ICUI, ICUI, IART, IART, IART, IART, IART, ELGX, ELGX, ELGX, ELGX, ELGX, NUVA, NUVA, NUVA, NUVA, NUVAPiper Jaffray to hold a bus tour
7th Annual SoCal Medtech & Diagnostics Bus Tour to travel throughout San Diego on August 25-28.
News For EW;ELGX;IART;ICUI;CFN;ATEC;VOLC;TNDM;SQNM;QDEL;NUVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 29, 2015
10:00 EDTIART, NUVAOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: 3D Systems (DDD) upgraded to Neutral from Underperform at Longbow... AK Steel (AKS) upgraded to Outperform from Neutral at Macquarie... Ally Financial (ALLY) upgraded to Outperform from Neutral at Credit Suisse... Amazon.com (AMZN) upgraded to Buy from Hold at Stifel... Arrow Electronics (ARW) upgraded to Buy from Underperform at CLSA... Beacon Roofing (BECN) upgraded to Buy from Neutral at CL King... Citrix (CTXS) upgraded to Outperform at Baird... Commvault (CVLT) upgraded to Buy from Hold at Jefferies... FireEye (FEYE) upgraded on positive checks, business mdoel changes at Oppenheimer... Hibbett Sports (HIBB) upgraded to Neutral from Underperform at Sterne Agee CRT... Integra LifeSciences (IART) upgraded to Outperform at Raymond James... M/A-COM (MTSI) upgraded to Buy from Hold at Needham... Norsk Hydro (NHYDY) upgraded to Neutral from Underperform at Exane BNP Paribas... NuVasive (NUVA) upgraded to Outperform from Market Perform at Northland... SM Energy (SM) upgraded to Outperform from Market Perform at Raymond James... Scorpio Bulkers (SALT) upgraded to Buy from Hold at Deutsche Bank... Sirius XM (SIRI) upgraded to Buy from Hold at Wunderlich... Sprouts Farmers Markets (SFM) upgraded to Neutral from Underperform at Longbow... Supervalu (SVU) upgraded to Equal Weight from Underweight at Morgan Stanley... Waters (WAT) upgraded to Outperform from Market Perform at Wells Fargo... Wells Fargo (WFC) upgraded to Buy from Neutral at Guggenheim... Williams-Sonoma (WSM) upgraded to Overweight from Neutral at JPMorgan... YRC Worldwide (YRCW) upgraded to Strong Buy at Raymond James.
09:20 EDTNUVANuVasive upgraded to Outperform, expects strong 2H at Northland
As previously reported, Northland upgraded NuVasive to Outperform from Market Perform and raised its price target to $68 from $48. The firm expects 2H results to beat expectations and is a buyer ahead of Q3 results given strength in the U.S. spine market, operating performance, and leverage. Northland views the iGA platform as a "game changer" and checks show NuVasive continues to take market share.
07:58 EDTEWEdwards Lifesciences price target raised to $179 from $157 at Stifel
Subscribe for More Information
07:46 EDTEWEdwards Lifesciences price target raised to $178 from $160 at Canaccord
Subscribe for More Information
07:44 EDTNUVANuVasive price target raised to $65 from $57 at Leerink
Leerink raised its price target for NuVasive to $65 saying the margin improvement story "has legs" following the company's Q2 results. The firm reiterates an Outperform rating on the stock.
07:43 EDTEWEdwards Lifesciences price target raised to $185 from $155 at Leerink
Subscribe for More Information
07:39 EDTIARTIntegra LifeSciences upgraded to Outperform at Raymond James
Raymond James upgraded Integra LifeSciences to Outperform from Market Perform with a $73 price target. The firm said execution is improving, visibility is at a high, and the high margin product cycle coupled with capital deployment should improve sentiment and drive shares higher.
07:23 EDTEWEdwards Lifesciences price target raised to $168 from $155 at JPMorgan
Subscribe for More Information
07:22 EDTNUVANuVasive upgraded to Outperform from Market Perform at Northland
July 28, 2015
16:31 EDTNUVANuVasive reaches definitive agreement with U.S. DOJ
Subscribe for More Information
16:30 EDTEWEdwards Lifesciences sees Q3 EPS 92c-$1.00, consensus 98c
Sees Q3 revenue $580M-$620M, consensus $587.06M.
16:28 EDTEWEdwards Lifesciences raises FY15 EPS view to $4.30-44.40, consensus $4.28
Backs FY15 revenue view $2.3B-$2.5B, consensus $2.41B
16:26 EDTEWEdwards Lifesciences reports Q2 EPS $1.13 , consensus $1.05
Subscribe for More Information
16:20 EDTNUVANuVasive raises 2015 EPS outlook to $1.17 from $1.10, consensus $1.12
Sees 2015 revenue $810M, consensus $812.22M.
16:19 EDTNUVANuVasive reports Q2 EPS 31c, consensus 25c
Subscribe for More Information
16:18 EDTNUVANuVasive enters $13.5M settlement of Justice Department
NuVasive announced that it has reached a definitive settlement with the U.S. Department of Justice related to the subpoena issued to the company by the Office of Inspector General of the Department of Health and Human Services in 2013. NuVasive admits no wrongdoing as part of the settlement. On April 29, the company announced that it had reached an agreement in principle to settle the investigation with the DOJ. The company has now entered into a definitive settlement agreement with the United States, acting through DOJ and on behalf of OIG, the Defense Health Agency, the Office of Personnel Management, and the U.S. Department of Veteran Affairs. Under the terms of the settlement agreement, the company will pay $13.5M, plus fees and accrued interest. The settlement is neither an admission of liability or wrongdoing by the company nor a concession by the United States that its claims are not well founded. The company was not required to enter into a corporate integrity agreement by the OIG as part of the settlement.
15:21 EDTNUVA, EWNotable companies reporting after market close
Subscribe for More Information
July 22, 2015
16:17 EDTQDELQuidel reports Q2 EPS (14c), consensus (25c)
Subscribe for More Information
July 20, 2015
07:33 EDTQDELInternational AIDS Society to hold a conference
Subscribe for More Information
06:04 EDTIARTSeaSpine selling pressure may be over, says at Piper Jaffray
Piper Jaffray points out that shares of SeaSpine (SPNE) are down 15% since their spin-off from Integra LifeSciences (IART) on June 17. Piper attributes the weakness to non-fundamental selling by existing Integra shareholders and its analysis indicates that the worst of the selling pressure might be over. The firm keeps an Overweight rating on SeaSpine with a $24 price target.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use